This Company Wants to Rewrite the Future of Genetic Disease

Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA—something that Crispr can't do.

source https://www.wired.com/story/this-company-wants-to-rewrite-the-future-of-genetic-disease